XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 15 - Stock Based Compensation
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

NOTE 15: STOCK BASED COMPENSATION

 

Stock Option and Incentive Plan

 

On March 24, 2020, the Board of Directors approved the adoption of the 2020 Stock Incentive Plan (2020 Plan) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. No awards may be granted under the 2020 Plan after the date that is 10 years from the date of stockholder approval. An aggregate of 3,000 shares were initially reserved for issuance in connection with awards granted under the 2020 Plan. On  May 14, 2021, the stockholders approved an additional 15,000 shares available for issuance under the 2020 Plan. There are 8,256 options available for grant under the 2020 Plan as of September 30, 2022.

 

The Company granted options to purchase 30 and 3,879 shares of common stock, respectively, to employees during the three and nine months ended September 30, 2022. For the three and nine months ended September 30, 2021, the Company granted 175 and 3,819 options, respectively, to employees to purchase shares of common stock. The weighted average grant date fair value of options granted during the three and nine months ended September 30, 2022, was $0.92 and $0.99, respectively, and $2.74 and $2.56 for the same periods in 2021, respectively. There were no options exercised during the three and nine months ended September 30, 2022. There were 699 options exercised during the three and nine months ended September 30, 2021, at an average exercise price of $2.46.  

 

The fair value of stock options granted for the three and nine months ended September 30, 2022 and 2021, was calculated using the Black-Scholes option-pricing model applying the following assumptions:

 

  

Three Months Ended September 30,

  Nine Months Ended September 30, 
  

2022

  2022 

Risk-free interest rate

 2.74%-2.88%  1.86%-3.02% 

Expected term (in years)

 5.30-5.31  5.19-6.11 

Dividend yield

  -    -  

Expected volatility

  117%    114%-128%  

 

  

Three Months Ended September 30,

  Nine Months Ended September 30, 
  

2021

  2021 

Risk-free interest rate

 0.89%-0.98%  0.89%-1.08% 

Expected term (in years)

 5.54-6.12  5.31-6.17 

Dividend yield

  -    -  

Expected volatility

  123%- 126%   122%-130%  
 
                     Compensation costs associated with the Company’s stock options are recognized based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense, which was included in the following captions in the consolidated statements of operations:

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2022

  

2021

  

2022

  

2021

 

General and administrative

 $1,042  $1,232  $3,366  $2,534 

Research and development

  624   562   1,877   1,114 

Total stock compensation expense

 $1,666  $1,794  $5,243  $3,648 

 

Options issued and outstanding as of September 30, 2022 and related activities during the nine months ended September 30,2022 were as follows:

 

  

Number of
Underlying
Shares

  

Weighted-
Average
Exercise Price
Per Share

  

Weighted-
Average
Contractual
Life Remaining
in Years

  

Aggregate
Intrinsic Value

 

Outstanding as of January 1, 2022

  10,027  $2.82   -     

Granted

  3,879   1.16   -   50,738 

Exercised

  -   -   -    

Forfeited / cancelled

  (200)  0.91   -     

Expired

  -   -   -   - 

Outstanding as of September 30, 2022

  13,706   2.37   8.04  $- 

Exercisable as of September 30, 2022

  9,354   2.65   7.52    

Vested and expected to vest

  13,706  $2.37   8.04  $- 

 

On September 30, 2022, there were 4,352 unvested options outstanding, and the related unrecognized total compensation cost associated with these options was $5,606. This expense is expected to be recognized over a weighted-average period of 1.13 years.